FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110384737> ?p ?o ?g. }

• W2110384737 endingPage "4" @default.
• W2110384737 startingPage "4730" @default.
• W2110384737 abstract "Loss or abnormal expression of Cyclin D2, a crucial cell cycle-regulatory gene, has been described in human cancers; however, data for prostate tumors are lacking. We investigated the epigenetic silencing of Cyclin D2 gene in prostate cancers and correlated the data with clinicopathological features.Cyclin D2 promoter methylation was analyzed in 101 prostate cancer samples by methylation-specific PCR. In addition, we analyzed 32 nonmalignant prostate tissue samples, which included 24 samples of benign disease, benign prostatic hypertrophy, or prostatitis and 7 normal tissues adjacent to cancer. The methylation status of Cyclin D2 was correlated with the methylation of nine other tumor suppressor genes published previously from our laboratory on the same set of samples (R. Maruyama et al., Clin. Cancer Res., 8: 514-519, 2002). The methylation index was determined as a reflection of the methylated fraction of the genes examined.The frequency of methylation of Cyclin D2 promoter was significantly higher in prostate cancers (32%) than in nonmalignant prostate tissues (6%; P = 0.004), and it was not age related. Aberrant methylation was present at insignificant levels in peripheral blood lymphocytes (8%). We also compared methylation of cyclin D2 with methylation of nine tumor suppressor genes [published previously from our laboratory (R. Maruyama et al., Clin. Cancer Res., 8: 514-519, 2002)] studied in the same set of samples. The concordances between methylation of Cyclin D2 and the methylation of RARbeta, GSTP1, CDH13, RASSF1A, and APC were statistically significant, whereas methylation of P16, DAPK, FHIT, and CDH1 were not significant. The differences in methylation index between malignant and nonmalignant tissues for all 10 genes were statistically significant (P < 0.0001). Among clinicopathological correlations, the high Gleason score group had significantly greater methylation frequency of Cyclin D2 (42%; P = 0.004). Although the high preoperative serum prostate-specific antigen (PSA) group did not have significantly greater methylation frequency, methylation of Cyclin D2 had higher mean PSA value. Also, the prostate cancers in the high Gleason score group had high mean values of PSA.Our results indicate that methylation of Cyclin D2 in prostate cancers correlates with clinicopathological features of poor prognosis. These findings are of biological and potential clinical importance." @default.
• W2110384737 created "2016-06-24" @default.
• W2110384737 creator A5012735404 @default.
• W2110384737 creator A5018387825 @default.
• W2110384737 creator A5033831640 @default.
• W2110384737 creator A5038077662 @default.
• W2110384737 creator A5048865240 @default.
• W2110384737 creator A5059166265 @default.
• W2110384737 creator A5068176453 @default.
• W2110384737 creator A5073852389 @default.
• W2110384737 date "2003-10-15" @default.
• W2110384737 modified "2023-09-29" @default.
• W2110384737 title "Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation." @default.
• W2110384737 cites W1489006980 @default.
• W2110384737 cites W1542585825 @default.
• W2110384737 cites W1552528612 @default.
• W2110384737 cites W1571410968 @default.
• W2110384737 cites W1604949025 @default.
• W2110384737 cites W1761725668 @default.
• W2110384737 cites W1969255091 @default.
• W2110384737 cites W1994465394 @default.
• W2110384737 cites W2006115709 @default.
• W2110384737 cites W2019510283 @default.
• W2110384737 cites W2027308884 @default.
• W2110384737 cites W2029086873 @default.
• W2110384737 cites W2029484950 @default.
• W2110384737 cites W2034269086 @default.
• W2110384737 cites W2035531485 @default.
• W2110384737 cites W2046509449 @default.
• W2110384737 cites W2050358666 @default.
• W2110384737 cites W2052465225 @default.
• W2110384737 cites W2056795663 @default.
• W2110384737 cites W2063063246 @default.
• W2110384737 cites W2070147996 @default.
• W2110384737 cites W2077253279 @default.
• W2110384737 cites W2086201558 @default.
• W2110384737 cites W2095816043 @default.
• W2110384737 cites W2123206370 @default.
• W2110384737 cites W2131954674 @default.
• W2110384737 cites W2137084288 @default.
• W2110384737 cites W2144434078 @default.
• W2110384737 cites W2155103945 @default.
• W2110384737 cites W2167896954 @default.
• W2110384737 cites W2407368528 @default.
• W2110384737 cites W2409495547 @default.
• W2110384737 cites W273460782 @default.
• W2110384737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14581343" @default.
• W2110384737 hasPublicationYear "2003" @default.
• W2110384737 type Work @default.
• W2110384737 sameAs 2110384737 @default.
• W2110384737 citedByCount "39" @default.
• W2110384737 countsByYear W21103847372012 @default.
• W2110384737 countsByYear W21103847372013 @default.
• W2110384737 countsByYear W21103847372014 @default.
• W2110384737 countsByYear W21103847372015 @default.
• W2110384737 countsByYear W21103847372016 @default.
• W2110384737 countsByYear W21103847372017 @default.
• W2110384737 countsByYear W21103847372019 @default.
• W2110384737 countsByYear W21103847372020 @default.
• W2110384737 countsByYear W21103847372021 @default.
• W2110384737 countsByYear W21103847372022 @default.
• W2110384737 countsByYear W21103847372023 @default.
• W2110384737 crossrefType "journal-article" @default.
• W2110384737 hasAuthorship W2110384737A5012735404 @default.
• W2110384737 hasAuthorship W2110384737A5018387825 @default.
• W2110384737 hasAuthorship W2110384737A5033831640 @default.
• W2110384737 hasAuthorship W2110384737A5038077662 @default.
• W2110384737 hasAuthorship W2110384737A5048865240 @default.
• W2110384737 hasAuthorship W2110384737A5059166265 @default.
• W2110384737 hasAuthorship W2110384737A5068176453 @default.
• W2110384737 hasAuthorship W2110384737A5073852389 @default.
• W2110384737 hasConcept C104317684 @default.
• W2110384737 hasConcept C121608353 @default.
• W2110384737 hasConcept C150194340 @default.
• W2110384737 hasConcept C190727270 @default.
• W2110384737 hasConcept C199835354 @default.
• W2110384737 hasConcept C2776235491 @default.
• W2110384737 hasConcept C2778264664 @default.
• W2110384737 hasConcept C2780192828 @default.
• W2110384737 hasConcept C2780733254 @default.
• W2110384737 hasConcept C29537977 @default.
• W2110384737 hasConcept C33288867 @default.
• W2110384737 hasConcept C41091548 @default.
• W2110384737 hasConcept C502942594 @default.
• W2110384737 hasConcept C54355233 @default.
• W2110384737 hasConcept C555283112 @default.
• W2110384737 hasConcept C86803240 @default.
• W2110384737 hasConceptScore W2110384737C104317684 @default.
• W2110384737 hasConceptScore W2110384737C121608353 @default.
• W2110384737 hasConceptScore W2110384737C150194340 @default.
• W2110384737 hasConceptScore W2110384737C190727270 @default.
• W2110384737 hasConceptScore W2110384737C199835354 @default.
• W2110384737 hasConceptScore W2110384737C2776235491 @default.
• W2110384737 hasConceptScore W2110384737C2778264664 @default.
• W2110384737 hasConceptScore W2110384737C2780192828 @default.
• W2110384737 hasConceptScore W2110384737C2780733254 @default.
• W2110384737 hasConceptScore W2110384737C29537977 @default.
• W2110384737 hasConceptScore W2110384737C33288867 @default.

• next